DexCom (DXCM) Slid on Poor Execution and GLP-1 Drug Disruption Concerns

DexCom (DXCM) Slid on Poor Execution and GLP-1 Drug Disruption Concerns
Sands Capital's Q4 2024 investor letter highlighted their Select Growth Fund's performance, focusing on companies leading in economic transformation. The fund outperformed the Russell 1000 Growth Index but noted DexCom, Inc.